Addition of low dose total body irradiation to fludarabine melphalan reduced intensity conditioning is feasible, tolerable, and may improve outcomes in patients with high-risk acute myeloid leukaemia and other high risk myeloid malignancies

Am J Hematol. 2015 May;90(5):E97-100. doi: 10.1002/ajh.23974. Epub 2015 Mar 2.

Authors

Grace Gifford¹, Kelly Wong, Ian Kerridge, William Stevenson, Chris Arthur, Keith Fay, Matthew Greenwood

Affiliation

¹ Haematology Department, Royal North Shore Hospital, Sydney, New South Wales, Australia.

PMID: 25683457
DOI: 10.1002/ajh.23974

No abstract available

Publication types

Letter

MeSH terms

Aged
Combined Modality Therapy
Drug Administration Schedule
Female
Hematologic Neoplasms / genetics
Hematologic Neoplasms / mortality
Hematologic Neoplasms / pathology
Hematologic Neoplasms / therapy*
Hematopoietic Stem Cell Transplantation*
Humans
Karyotyping
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / pathology
Leukemia, Myeloid, Acute / therapy*
Male
Melphalan / therapeutic use*
Middle Aged
Myeloablative Agonists / therapeutic use
Survival Analysis
Transplantation Conditioning / methods*
Treatment Outcome
Vidarabine / analogs & derivatives*
Vidarabine / therapeutic use
Whole-Body Irradiation / methods*

Substances

Myeloablative Agonists
Vidarabine
fludarabine
Melphalan